Luye Pharma Group (HKSE:02186) Cash And Cash Equivalents : HK$6,185 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Luye Pharma Group Cash And Cash Equivalents?

Luye Pharma Group's quarterly cash and cash equivalents declined from Dec. 2022 (HK$6,164.57 Mil) to Jun. 2023 (HK$4,892.23 Mil) but then increased from Jun. 2023 (HK$4,892.23 Mil) to Dec. 2023 (HK$6,185.11 Mil).

Luye Pharma Group's annual cash and cash equivalents increased from Dec. 2021 (HK$2,985.56 Mil) to Dec. 2022 (HK$6,164.57 Mil) and increased from Dec. 2022 (HK$6,164.57 Mil) to Dec. 2023 (HK$6,185.11 Mil).

Luye Pharma Group Cash And Cash Equivalents Historical Data

The historical data trend for Luye Pharma Group's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Luye Pharma Group Cash And Cash Equivalents Chart

Luye Pharma Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

2,589.76

4,582.15

2,985.56

6,164.57

6,185.11

Luye Pharma Group Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Cash And Cash Equivalents	Get a 7-Day Free Trial															2,985.56	3,953.62	6,164.57	4,892.23	6,185.11

Luye Pharma Group Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Luye Pharma Group (HKSE:02186) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Luye Pharma Group Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Luye Pharma Group's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Luye Pharma Group (HKSE:02186) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Luye Pharma Group Ltd (HKSE:02186) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

LYPHF:USA LUP:Germany LUP:Germany

Address

No. 15 Chuang Ye Road, High-tech Industrial Development Zone, Shandong, Yantai, CHN, 264003

Website

https://www.luye.cn

Luye Pharma Group Ltd is a China-based drug manufacturer that focuses on developing, producing, and selling pharmaceutical products. The company develops drugs related to diagnosing and treating cancer, the cardiovascular system, the alimentary tract, and the central nervous system. The company's highest revenue share comes from oncology drugs, followed by central nervous system drugs. The company develops drugs for global use in Asia, Europe, and the United States.

Executives

Ubs Group Ag	2201 Interest of corporation controlled by you
Liu Dianbo	2301 Trustee
Luye Life Sciences Group Ltd	2201 Interest of corporation controlled by you
Luye Pharma Holdings Ltd.	2201 Interest of corporation controlled by you
Nelumbo Investments Limited	2201 Interest of corporation controlled by you
Shorea Lbg	2201 Interest of corporation controlled by you
Luye Pharmaceutical Investment Co., Ltd.	2101 Beneficial owner
Ginkgo (ptc) Limited	2301 Trustee
Luye Pharmaceutical International Co., Ltd.	2201 Interest of corporation controlled by you
Yi Fang Da Ji Jin Guan Li You Xian Gong Si	2102 Investment manager
Hillhouse Nev Holdings Limited	2101 Beneficial owner
Hillhouse Investment Management, Ltd.	2102 Investment manager
Hillhouse Fund V, L.p.	2201 Interest of corporation controlled by you
Xin Ye Sheng Wu Yi Yao Kong Gu You Xian Gong Si
Yang Yu Fen

Luye Pharma Group (HKSE:02186) Headlines

No Headlines